Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
1 hedge funds and large institutions have $2.8M invested in Provention Bio, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 180 closing their positions.
99% less funds holding
Funds holding: 182 → 1 (-181)
100% less capital invested
Capital invested by funds: $1.47B → $2.8M (-$1.47B)
100% less funds holding in top 10
Funds holding in top 10: 9 → 0 (-9)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 180
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sessa Capital
New York
|
-$214M |
| 2 |
BlackRock
New York
|
-$137M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$101M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$87.7M |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$75.6M |
PRVB Hedge Fund Activity: Q2 2023 in Review
1 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q2 2023, worth a combined $2.8M — down 100% from $1.47B a quarter earlier.
Sellers outnumbered buyers: 180 funds closed out of PRVB and 0 opened new positions — a net loss of 180 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Sessa Capital, exiting entirely with an estimated $214M sold.
- 1 institutional investor held Provention Bio, Inc. Common Stock (PRVB) as of Q2 2023, down from 182 in Q1 2023.
- Funds reported $2.8M of Provention Bio, Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Provention Bio, Inc. Common Stock positions in Q2 2023 and 180 closed out, a net change of -180 holders.
- The largest Provention Bio, Inc. Common Stock seller in Q2 2023 was Sessa Capital, an estimated $214M sold.
Based on aggregated 13F filings for Q2 2023.